The $200 million plus round brings together lead investor AON Consulting, Inc., with prominent investors such as NFL legend and eMed Founding Chief Wellness Officer Tom Brady, alongside Jeff Aronin, Founder, Chairman and CEO of Paragon Biosciences; Ara Cohen, Co-Founder and Co-Managing Member of Knighthead Capital Management; Antonio Gracias, Founder and CEO of Valor Equity Partners; Joe Lonsdale, Founder and Managing Partner at 8VC and Co-Founder of Palantir; R.J. Melman, CEO, Lettuce Entertain You Restaurants; Tom Ricketts, Chairman of the Chicago Cubs; and former X CEO and current eMed CEO Linda Yaccarino.

eMed is the gold standard in clinically managed GLP-1 programs for employers. At the core is a fundamental reality: GLP-1s are among the most significant therapeutic advances of our time, but their impact is only realized when patients stay on treatment. By achieving more than 90% member adherence, more than double the industry norm, eMed's program delivers what others cannot: employees who stay the course and see real results, including an average weight loss of 21 pounds, with 99% seeing improvement in at least one key biomarker within six months.